文献速递肝肾功能剂量调整特殊人群用药

2002至2024年FDA批准药物中的儿科肝功能不全剂量推荐

Pediatric Hepatic Impairment Dosing in FDA Approvals Between 2002 and 2024.
PubMed 文献 · Clin Pharmacol Ther · 2025-07-24

研究审查了61个同时具有儿科适应症且在用法用量部分提及「肝」的FDA批准药物,仅8个包含儿科特异性肝功能不全剂量推荐,其中7个基于Child-Pugh分级。支持这些推荐的证据主要来自成人肝功能不全药代动力学研究,仅1个药物在轻度肝功能不全儿科患者中评估。Lexicomp和Micromedex与说明书推荐一致且未引用额外证据。儿科肝功能不全剂量推荐存在明显证据缺口。

要点

  • 61个药物中仅8个有儿科特异性肝功能不全剂量推荐,7个基于Child-Pugh分级
  • 8个药物的推荐证据主要来自成人肝功能不全药代动力学研究
  • 仅1个药物在轻度肝功能不全儿科患者中进行了评估

核心结论

  • 儿科肝功能不全患者的剂量推荐存在明显证据缺口,多数推荐缺乏儿科直接证据支持。

研究设计与样本

  • 审查美国FDA处方信息中同时具有儿科适应症且在用法用量部分含「肝」字的61个药物,并对照Lexicomp和Micromedex儿科剂量手册。

主要发现

  • 61个药物中仅8个包含儿科特异性肝功能不全剂量推荐,其中7个基于Child-Pugh分类。
  • 8个药物的推荐证据主要来自成人肝功能不全药代动力学研究,仅1个药物在轻度肝功能不全儿科患者中评估。
  • Lexicomp和Micromedex提供的肝功能不全剂量推荐与处方信息一致,且未引用额外证据。

关键数值与推荐

  • 61个药物中8个有儿科特异性肝功能不全剂量推荐,7个基于Child-Pugh分类。
  • 仅1个药物在轻度肝功能不全儿科患者中进行了评估。

临床怎么用

  • 临床为肝功能不全儿科患者制定剂量时,应认识到现有推荐多基于成人数据和Child-Pugh分类,儿科直接证据有限。
  • Lexicomp和Micromedex的肝功能不全剂量推荐与FDA处方信息一致,可作为参考但需注意证据来源。

局限性

  • 肝功能不全在儿科药物开发中很少被评估,原因包括患者数量少、成人与儿科肝病差异及缺乏公认的严重程度评估标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The safety and efficacy of drugs metabolized by the liver can be substantially impacted by alterations in hepatic function. However, hepatic impairment (HI) is rarely evaluated in pediatric drug development due to challenges such as the relatively small number of patients, differences in adult and pediatric liver disease, and the lack of agreed-upon markers to assess HI severity. The objectives of the study were to (1) examine adult and pediatric HI dosing recommendations in US FDA prescribing information (PI) and pediatric dosing handbooks, Lexicomp and Micromedex, and (2) identify the clinical evidence behind HI dosing recommendations for pediatric patients. A total of 61 drugs containing both a pediatric indication and the word "hepatic" in the Dosage and Administration section of the PI were reviewed. Of the 61 drugs, only eight drugs included pediatric-specific HI dosing recommendations, with seven based on the Child-Pugh classification. Pharmacokinetic studies in adults with HI were the primary evidence behind the recommendations for all eight drugs, and only one drug was evaluated in pediatric patients with mild HI. Lexicomp and Micromedex provided consistent HI dosing recommendations with the PI and did not cite additional evidence. Overall, there is a gap in dosing recommendations for pediatric patients with HI. Alternative approaches, such as modeling and simulation based on drug- and disease-specific parameters, may help address knowledge gaps for pediatric patients with HI in the future.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Cassel DA, Burckart GJ, Sahre MD, et al. Pediatric Hepatic Impairment Dosing in FDA Approvals Between 2002 and 2024. Clin Pharmacol Ther. 2025. PMID: 40708278. doi:10.1002/cpt.70011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。